Clinical Trials
3 trialsNCT00516373 2024-02-22
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
AstraZeneca
Phase 1 Completed
NCT02418624 2019-01-16
REVIVAL
The Netherlands Cancer Institute
Phase 1 Completed
NCT01286987 2019-01-10
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
Phase 1 Completed